{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T08:51:09Z","timestamp":1778403069497,"version":"3.51.4"},"reference-count":8,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatology"],"published-print":{"date-parts":[[2004]]},"abstract":"<jats:p>&lt;i&gt;Background: &lt;\/i&gt;Two recent studies have provided opposite results on the efficacy of naltrexone on uremic pruritus. We have performed a third study. &lt;i&gt;Objective: &lt;\/i&gt;To compare the efficacy and tolerance of naltrexone and loratadine in uremic pruritus. &lt;i&gt;Patients\/Methods: &lt;\/i&gt;Among 296 hemodialyzed patients, 65 suffered from uremic pruritus. Fifty-two patients participated in the study. The patients were treated for 2 weeks with naltrexone (50 mg\/day; 26 patients) or loratadine (10 mg\/day; 26 patients), after a washout of 48 h. Pruritus intensity was scored by a visual analogue scale (VAS). Adverse events were carefully searched for. The two groups were statistically equivalent. &lt;i&gt;Results: &lt;\/i&gt;There was no significant difference in the mean VAS scores after treatment, but naltrexone allowed a dramatic decrease in VAS scores (\u0394 &gt;3\/10) in 7 patients. Adverse events (mainly nausea and sleep disturbances) were observed in 10\/26 patients. &lt;i&gt;Conclusions: &lt;\/i&gt;Naltrexone is effective only in a subset of patients. Adverse events are very frequent. The differences of efficacy and tolerance between patients might be due to metabolism. Naltrexone might be considered as a second-line treatment.<\/jats:p>","DOI":"10.1159\/000077841","type":"journal-article","created":{"date-parts":[[2004,6,9]],"date-time":"2004-06-09T07:33:23Z","timestamp":1086766403000},"page":"326-330","source":"Crossref","is-referenced-by-count":75,"title":["A Comparative Study on the Effects of Naltrexone and Loratadine on Uremic Pruritus"],"prefix":"10.1159","volume":"208","author":[{"given":"Emmanuelle","family":"Legroux-Crespel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Cl\u00e8des","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Misery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2004,6,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/0923-1811(95)00451-W"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-139x.2000.00050.x"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)04176-1"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1159\/000046272"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.118.3.154"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1159\/000045371"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/1099-0801(200005)14:3<151::AID-BMC941>3.0.CO;2-E"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1159\/000044967"}],"container-title":["Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/77841","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/77841","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T03:08:14Z","timestamp":1745464094000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000077841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004]]},"references-count":8,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2004,6,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000077841","archive":["Portico"],"relation":{},"ISSN":["1018-8665","1421-9832"],"issn-type":[{"value":"1018-8665","type":"print"},{"value":"1421-9832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004]]}}}